secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001193125-25-202760
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa and Novartis expand collaboration for immune-disease degraders; upfront $120M
--------------------------------------------------------------------------------

- Monte Rosa receives $120M upfront from Novartis under new collaboration for degraders in immune-mediated diseases.
- Up to $5.7B in total milestone payments plus tiered royalties (high single to low double-digits) across up to three programs.
- Novartis gets exclusive license to one undisclosed discovery target and options on two additional preclinical I&I programs.
- Second collaboration with Novartis; first (VAV1/MRT-6160) was announced Oct 2024.
- Extended cash runway accelerates preclinical and clinical-stage immunology pipeline; Phase 2 readouts expected for MRT-8102, MRT-6160, MRT-2359.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000119312525202760/0001193125-25-202760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000119312525202760/glue-20250915.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-202760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer